Brief: Irlab Therapeutics Says Pirepemat Treatment Effect Did Not Reach Statistical Significance Compared To Placebo
05/03/2025 12:47
March 5 (Reuters) - IRLAB Therapeutics AB IRLABa.ST: REPORTS TOPLINE RESULTS FROM A PHASE IIB STUDY OF PIREPEMAT IN PATIENTS WITH PARKINSON'S DISEASE EFFECT DID NOT REACH STATISTICAL SIGNIFICANCE COMPARED TO PLACEBO RESULTS SHOW TREATMENT WITH PIREPEMAT (600 MG DAILY) REDUCED FALL RATE BY 42% AMONG INDIVIDUALS WITH PARKINSON'S DISEASE ADVERSE EVENT PROFILE WAS CONSISTENT WITH PREVIOUSLY REPORTED CLINICAL TRIAL RESULTS FOR PIREPEMAT DURING STUDY, ONE DEATH WAS REPORTED FOR A PARTICIPANT RECEIVING PLACEBO Source text: ID:nMFN65l5bh Further company coverage: [IRLABa.ST] (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))